Summary of key recommendations: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 21: | Line 21: | ||
*Moderate-intensity statin | *Moderate-intensity statin | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL | ||
*Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | *Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
*Re-emphasize heart-healthy lifestyle habits and address other risk factors | *Re-emphasize heart-healthy lifestyle habits and address other risk factors | ||
** ‡7.5% 10-y ASCVD risk: Moderate- or high-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ** ‡7.5% 10-y ASCVD risk: Moderate- or high-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
===C. Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments=== | ===C. Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments=== |
Revision as of 18:24, 27 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
A. Heart-healthy lifestyle habits should be encouraged for all individuals
B. The appropriate intensity of statin therapy should be initiated or continued
Class I |
"1.Clinical ASCVD which includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin (Level of Evidence: A) "
|
"2.Primary prevention – Primary LDL-C ‡190 mg/dL (Level of Evidence: B) "
|
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL (Level of Evidence: A) "
|
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
|
C. Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments
Class I |
"1.Assess adherence, response to therapy, and adverse effects within 4–12 wk following statin initiation or change in therapy
|
D. In individuals intolerant of the recommended intensity of statin therapy, use the maximally tolerated intensity of statin
Class I |
"1. If there are muscle or other symptoms, establish that they are related to the statin (Level of Evidence: A) " |
Class III (Harm) |
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
Class III (No Benefit) |
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
Class IIa |
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
Class IIb |
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |